AU
UK
CA
NZ
IND
US
Last update at 2026-06-04T13:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Knight to Participate in Crescita Rights Offering
Tue 20 Feb 18, 11:00 AMKnight participera à l'offre de droits dans Crescita
Tue 20 Feb 18, 11:00 AMKnight Increases Ownership in Crescita
Tue 10 Oct 17, 12:00 PMKnight accroît sa participation dans Crescita
Tue 10 Oct 17, 12:00 PMKnight Supports Crescita Trajectory
Mon 14 Aug 17, 12:35 PMKnight appuie le parcours de Crescita
Mon 14 Aug 17, 12:35 PMThérapeutique Knight inc. : INTEGA en pleine Crescita (croissance en italien)
Thu 01 Sep 16, 01:24 PMKnight Therapeutics Inc.: INTEGA Skin Primed for Crescita (Italian for Growth)
Thu 01 Sep 16, 01:23 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -0.08300M | -2.76400M | -1.53000M | 0.40M | -1.00900M |
| Minority interest | - | - | - | - | - |
| Net income | -0.09200M | -2.75000M | -1.98600M | 0.86M | -1.10500M |
| Selling general administrative | 10.82M | 10.81M | 10.12M | 10.57M | 8.55M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 10.37M | 9.61M | 10.36M | 13.18M | 10.01M |
| Reconciled depreciation | 1.50M | 1.37M | 1.51M | 1.47M | 1.38M |
| Ebit | -1.02200M | -2.69900M | -1.46100M | 0.73M | -0.52900M |
| Ebitda | 0.48M | -1.33300M | 0.04M | 2.20M | 0.85M |
| Depreciation and amortization | 1.50M | 1.37M | 1.51M | 1.47M | 1.38M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -1.02200M | -3.21500M | -1.95600M | 0.73M | -0.52900M |
| Other operating expenses | 22.14M | 22.80M | 19.48M | 23.00M | 17.49M |
| Interest expense | 0.04M | 0.07M | 0.09M | 0.16M | 0.24M |
| Tax provision | 0.00900M | -0.01400M | 0.46M | -0.45800M | 0.10M |
| Interest income | 0.33M | 0.34M | 0.51M | 0.26M | 0.24M |
| Net interest income | 0.29M | 0.43M | 0.42M | 0.10M | -0.05400M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.00900M | -0.01400M | 0.46M | -0.45800M | 0.10M |
| Total revenue | 21.12M | 19.58M | 17.52M | 23.52M | 16.77M |
| Total operating expenses | 11.39M | 12.82M | 12.32M | 12.65M | 10.73M |
| Cost of revenue | 10.74M | 9.97M | 7.16M | 10.34M | 6.75M |
| Total other income expense net | 0.94M | 0.45M | 0.43M | -0.32800M | -0.48000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -0.09200M | -2.75000M | -1.98600M | 0.86M | -1.10500M |
| Net income applicable to common shares | - | -2.75000M | -1.98600M | 0.86M | -1.10500M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 20.33M | 21.78M | 24.60M | 28.48M | 28.92M |
| Intangible assets | 1.46M | 1.74M | 1.99M | 2.87M | 3.74M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.31M | - | 0.20M | 0.39M | 0.62M |
| Total liab | 4.75M | 5.95M | 5.78M | 7.39M | 8.40M |
| Total stockholder equity | 15.58M | 15.83M | 18.82M | 21.10M | 20.53M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.05M | 0.05M | 0.10M | 5.65M | 5.38M |
| Common stock | 51.49M | - | 54.34M | 56.30M | 58.08M |
| Capital stock | 51.49M | 52.70M | 54.34M | 56.30M | 58.08M |
| Retained earnings | -45.44100M | -45.34900M | -42.59900M | -40.61300M | -41.47500M |
| Other liab | - | - | - | 0.12M | 0.15M |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | 0.46M | 2.18M |
| Cash | 8.58M | 9.27M | 9.38M | 8.24M | 11.33M |
| Cash and equivalents | - | - | - | 8.24M | 11.33M |
| Total current liabilities | 4.72M | 5.51M | 4.86M | 6.06M | 6.72M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -8.24300M | - | -8.13100M | -6.62500M | -8.46300M |
| Short term debt | 0.33M | - | 0.44M | 0.41M | 1.34M |
| Short long term debt | - | - | - | - | 0.98M |
| Short long term debt total | 0.33M | - | 1.25M | 1.61M | 2.87M |
| Other stockholder equity | 8.41M | - | 5.96M | 4.27M | 2.77M |
| Property plant equipment | - | - | - | 2.31M | 2.58M |
| Total current assets | 15.72M | 15.30M | 18.49M | 20.52M | 20.09M |
| Long term investments | 0.00000M | 0.31M | 0.36M | 0.34M | 0.34M |
| Net tangible assets | - | - | - | 18.23M | 16.79M |
| Short term investments | - | - | 0.00300M | - | - |
| Net receivables | 2.11M | 1.36M | 2.77M | 6.24M | 3.75M |
| Long term debt | - | - | - | - | 0.00000M |
| Inventory | 4.72M | 4.05M | 6.12M | 5.65M | 4.39M |
| Accounts payable | 4.33M | - | 4.33M | 5.59M | 5.33M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 1.12M | - | 1.12M | 1.13M | 1.15M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | 1.99M | 2.00M | 2.18M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 4.61M | 6.47M | 6.11M | 7.97M | 8.83M |
| Capital lease obligations | 0.33M | 0.83M | 1.25M | 1.61M | 1.89M |
| Long term debt total | - | - | - | 1.21M | 1.52M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -2.01900M | -0.13300M | -0.29000M | -0.84600M |
| Change to liabilities | - | - | - | 0.23M | 0.99M |
| Total cashflows from investing activities | -0.97300M | -2.01900M | -0.13300M | -0.29000M | -0.84600M |
| Net borrowings | -0.51500M | -0.44100M | -0.40800M | -1.37300M | -0.34900M |
| Total cash from financing activities | -0.78800M | -0.86100M | -0.78200M | -1.84600M | -0.50000M |
| Change to operating activities | - | - | - | 0.27M | -0.26700M |
| Net income | -0.09200M | -2.75000M | -1.98600M | 0.86M | -1.10500M |
| Change in cash | -0.69600M | -0.11200M | 1.15M | -3.09300M | -2.95000M |
| Begin period cash flow | 9.27M | 9.38M | 8.24M | 11.33M | 14.28M |
| End period cash flow | 8.58M | 9.27M | 9.38M | 8.24M | 11.33M |
| Total cash from operating activities | 1.07M | 2.73M | 2.08M | -1.02000M | -1.59700M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 1.50M | 1.37M | 1.51M | 1.47M | 1.38M |
| Other cashflows from investing activities | -0.64000M | -0.83400M | 0.00000M | -0.06100M | -0.50000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.55800M | 2.17M | -0.91700M | -1.78000M | -1.37500M |
| Change to account receivables | -0.17700M | 1.48M | 3.54M | -2.57200M | -1.04200M |
| Sale purchase of stock | -0.22300M | -0.32000M | -0.39300M | -0.42900M | -0.10100M |
| Other cashflows from financing activities | -0.05000M | -0.10000M | 0.02M | -0.04400M | -0.05000M |
| Change to netincome | - | - | - | 0.36M | -0.40500M |
| Capital expenditures | 0.33M | 1.19M | 0.13M | 0.23M | 0.35M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.18M | 3.91M | 1.81M | -3.71500M | -1.46600M |
| Stock based compensation | 0.07M | 0.18M | 0.08M | 0.22M | 0.27M |
| Other non cash items | -0.52800M | 0.03M | 0.21M | 0.60M | -0.77300M |
| Free cash flow | 0.74M | 1.54M | 1.94M | -1.24900M | -1.94300M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CTX Crescita Therapeutics Inc |
- -% | 0.79 | - | - | 0.65 | 0.88 | 0.26 | 3.79 |
| CURA Curaleaf Holdings Inc. |
11.14 219.72% | 16.21 | - | 138.89 | 2.57 | 3.14 | 2.47 | 13.10 |
| BHC Bausch Health Companies Inc |
0.18 2.46% | 7.49 | 13.98 | 1.35 | 0.28 | 18.74 | 2.12 | 6.84 |
| CRON Cronos Group Inc |
-0.05 1.28% | 3.85 | - | 32.15 | 9.80 | 0.95 | 1.47 | 1.90 |
| TLRY Tilray Inc |
-0.33 4.57% | 6.89 | - | 1000.00 | 1.28 | 0.53 | 1.08 | -2.299 |
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers and DuraPeel that supports the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud and Aquafolia brands; and medical aesthetics under the Pro-Derm and Alyria brands for non-invasive and minimally invasive procedures or skincare treatments. The company also distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; ART FILLER, a hyaluronic acid-based dermal filler; and MicronJet, an intradermal injection device. The company has commercialization license agreement with Cantabria Labs Inc.; and development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.
2805, Place Louis R Renaud, Laval, QC, Canada, H7V 0A3
| Name | Title | Year Born |
|---|---|---|
| Mr. Serge Verreault B.A., M.B.A. | Pres & CEO | NA |
| Mr. Jose DaRocha C.A., CPA | Chief Financial Officer | NA |
| Mr. Francois Lafortune | Exec. VP & GM | NA |
| Dominic King-Smith | VP of Bus. Devel. | NA |
| Mr. Serge Verreault B.A., M.B.A. | President, CEO & Director | NA |
| Ms. Linda Kisa | Vice-President of Reporting, Corporate Affairs & Secretary | NA |
| Ms. Linda Kisa C.A., CPA | Vice-President of Reporting, Corporate Affairs & Secretary | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...